氢氯噻嗪杂质9 | 364-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 中文名称: 氢氯噻嗪杂质9
• 中文别名: 6,7-二氯-3-甲基-4H-苯并[e][1,2,4]噻二嗪1,1-二氧化物
• 英文名称: 3-Methyl-6,7-dichlor-2H-1,2,4-benzothiadiazin-1,1-dioxid
• 英文别名: 6,7-Dichlor-3-methyl-2H-1,2,4-benzothiadiazin-1,1-dioxyd；6,7-dichloro-3-methyl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide；2H-1,2,4-Benzothiadiazine, 6,7-dichloro-3-methyl-, 1,1-dioxide；6,7-dichloro-3-methyl-4H-1λ6,2,4-benzothiadiazine 1,1-dioxide
• CAS: 364-96-5
• 化学式: C₈H₆Cl₂N₂O₂S
• 分子量: 265.12
• InChiKey: NJMWRGDFOPSHPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL
  申请人：De Boer Johannes Mathijs Maria

  公开号：US20100234362A1

  公开（公告）日：2010-09-16

  The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/l or less. The present invention also relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising orally administering to said mammal in need thereof a daily dosage of about 5 mg to about 1200 mg, calculated on a Diazoxide active weight basis.
• USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS
  申请人：De Boer Johannes Marthijs Maria

  公开号：US20120053172A1

  公开（公告）日：2012-03-01

  The present invention relates to a method for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, said method comprising administering to said mammal a pharmaceutically effective amount of a combination of a potassium channel activator and an anti-diabetic drug. The present invention also relates to a method for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising administering to said mammal a pharmaceutically effective amount of a combination of a potassium channel activator and an anti-diabetic drug.
• METHODS AND COMPOSITIONS FOR TREATING CANCER
  申请人：Globavir BioSciences, Inc.

  公开号：US20160361298A1

  公开（公告）日：2016-12-15

  Described are compositions and methods for treating cancer. Some methods comprise the administration of an effective amount of at least one inhibitor of tryptophan 2,3-dioxygenase (TDO) and/or indoleamine 2,3-dioxygenase (IDO), optionally combined with one or more additional anti-cancer agents.